Standards; Pharmaceutical/API Drug Impurities/Metabolites;
应用:
Palbociclib Impurity A is related to the parent compound, Palbocicib (P139900) (also known as compound number PD-0332991), which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Also, it is derived from 3-Fluoro-2-nitropyridine (F597685).
您的位置：
